
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Paratek Pharmaceuticals, Inc. | SEYSARA™ (sarecycline) | Inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older | Granted approval by the FDA |
Clovis Oncology, Inc. | Rubraca® (rucaparib) | BRCA1/2-mutated mCRPC after androgen receptor (AR)-directed therapy and taxane-based chemotherapy | Granted Breakthrough Therapy designation by the FDA |
PharmAbcine, Inc. | Bevacizumab (Avastin®) | Recurrent glioblastoma | Received “Study May Proceed Letter “ for IND application from the FDA; can initiate Phase II trials |
Amgen | KYPROLIS® (carfilzomib) | Relapsed or refractory multiple myeloma | FDA approved supplemental New Drug Application to expand prescribing information |
Applied BioCode | BioCode® Gastrointestinal Pathogen Panel on BioCode® MDx-3000 molecular system | Tests for 17 most common bacteria, viruses and parasites that cause infectious diarrhea | Granted 510 (k) clearance by the FDA |
Eisai Co., Ltd. | Fycompa (perampanel) | Partial-onset seizures in pediatric patients with epilepsy 4 years of age and older | Granted approval by the FDA for an indication expansion |
Eli Lilly and Company | Ultra Rapid Lispro (URLi) | Type 1 and Type 2 diabetes | Phase III clinical trials show met primary efficacy endpoint |
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited | ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) | CD30-expressing peripheral T-cell lymphoma (PTCL), also known as mature T-cell lymphoma (MTCL) | Phase III ECHELON-2 clinical trial met its primary endpoint |
Acorda Therapeutics, Inc. | INBRIJA, investigational inhaled levodopa | OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen | Releasing efficacy analysis from SPAN-PD, Phase III clinical trial |
Five Prime Therapeutics, Inc. | Bemarituzumab (FPA144), an isoform-selective FGF receptor 2b (FGFR2b) antibody, with chemotherapy | Advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer | First patient dosed in Phase III FIGHT pivotal trial |
Ocugen, Inc. | OCU310 | Dry eye | Initiated Phase III clinical trial |
PTC Therapeutics | Risdiplam (RG7916) | Type 1, 2 and 3 spinal muscular atrophy (SMA) | Interim data from open-label clinical trials show increases in developmental motor milestones |
Veloce BioPharma, LLC | VBP-926 (Povidone-Iodine) topical treatment | Chemo-associated paronychia, or painful, inflamed nails, a chemo side effect | Positive results of Phase IIb trial |
Upcoming Events
-
05Dec
-
14Apr